Locations:
Search IconSearch

Heart Valve Disease

23-HVI-4417336 CQD 650×450

Aortic Valve Reimplantation Shows Long-Term Durability in Patients With Connective Tissue Disorders

Many young patients can avoid lifelong anticoagulation with a valve-sparing approach

illustration of mitral valve transcatheter edge-to-edge repair

The Two FDA-Approved M-TEER Systems Are Comparable at 1-Year Follow-Up, CLASP IID Data Show

And substudy reveals good outcomes with PASCAL system in patients with complex mitral valve anatomy

illustration of tricuspid valve regurgitation

TRILUMINATE Health Status Analysis: T-TEER Patients Likelier to Be ‘Alive and Well’ at 1 Year

Investigators conclude that improved self-reports go beyond possible placebo effect for severe TR

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

23-HVI-4078932_severe-tricuspid-regurgitation_650x450

Early Surgery for Isolated Severe Tricuspid Regurgitation Improves Outcomes

Cleveland Clinic study argues against waiting for symptoms to develop

Blood Clot Cell Artery

PROACT Xa: Apixaban Is Not a Safe Warfarin Substitute With Mechanical Aortic Valve

Details released from the trial halted due to excessive thromboembolic events

23-HVI-3691658 mitral-valve-repair_650x450

Secrets to Success in Mitral Valve Repair

The cultural and technical factors promoting repair durability and a mortality-free stretch of 4,000+ cases

23-HVI-3606664 CQD 650×450 (1)

TRILUMINATE Pivotal Trial: What Are Its Implications for Tricuspid Regurgitation Care?

TEER is found to be a safe and good option for severe TR in select patients

23-HVI-3655709 CQD 650×450-c2

MAC Attack: Contending With Mitral Annular Calcification During Mitral Valve Surgery

Surgical tips on debridement of calcification to optimize valve replacement

BackPage 4 of 7Next

Advertisement

Ad